Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer

Fig. 2

Anti-proliferative effect of a RAD001 and b neratinib in endocrine-resistant and -sensitive BC cell lines. Cells were treated in the absence or presence of exogenous E2 (0.01 nM) and doubling concentrations of RAD001 or neratinib. Treatments were performed at day 1 and day 3 after seeding. After 6 days of treatment, cell viability was analysed using a cell titer-glo assay. Data are expressed as fold-change relative to dextran charcoal (DCC) control. Error bars represent mean ± SEM

Back to article page